Latest Research Study on Alpha Thalassemia
The Global Alpha Thalassemia Market reached US$ 1.1 billion in 2022 and is expected to reach US$ 1.9 billion by 2031 growing with a CAGR of 7.4% during the forecast period 2024-2031.
Alpha Thalassemia is a genetic blood disorder that affects the production of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. It occurs when one or more of the four alpha-globin genes are missing or mutated, leading to reduced hemoglobin levels and potential anemia. The severity of the condition depends on the number of defective genes inherited.
Alpha thalassemia is most prevalent in regions such as Southeast Asia, the Mediterranean, the Middle East, and Africa, where the thalassemia trait is commonly passed through generations. The condition ranges from silent carriers (with no symptoms) to Hemoglobin H disease, which can cause moderate to severe anemia, and the most severe form, alpha thalassemia major, which is often fatal before birth.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/alpha-thalassemia-market
Market Growth Drivers:
Growing Advancements and Clinical Trials by Key Players Drive the Growth of the Alpha Thalassemia Market
Ongoing clinical trials for alpha thalassemia are showing promising results. On November 15, 2022, a study published by the American Society of Hematology revealed that adenosine triphosphate (ATP) levels in thalassemic red blood cells (RBCs) are insufficient to meet their increased energy demands. Mitapivat, a drug that allosterically activates pyruvate kinase (PK)—a key enzyme in the final stage of glycolysis responsible for ATP production—has shown potential in addressing this deficiency.
In an earlier Phase 2 open-label study (NCT03692052), mitapivat was tested in patients with non-transfusion-dependent thalassemia (NTDT). The results showed that 80% of patients experienced a hemoglobin (Hb) increase of at least 1.0 g/dL between weeks 4 and 12. Additionally, hemolysis markers improved, and hemoglobin levels continued to rise, reaching an average increase of 1.7 g/dL at week 72. These findings highlight the potential of mitapivat as a breakthrough therapy for managing alpha thalassemia.
Rising Collaboration by Key Players for Research and Development Creates Opportunities for the Growth of the Market
Years of research have led to significant progress in the alpha thalassemia market, with major manufacturers now developing and launching novel therapies to address this rare condition. Several treatments have already been approved by regulatory authorities for managing alpha thalassemia, and key industry players are increasingly collaborating to develop new products for rare diseases, including thalassemia.
For example, on January 8, 2023, Amryt Pharma Plc, a commercial-stage biopharmaceutical company, announced its commitment to acquiring, developing, and marketing innovative treatments for rare diseases. In a significant move, Chiesi Farmaceutici S.p.A., a research-driven healthcare and biopharmaceutical group, confirmed its agreement to acquire Amryt, marking an important step in expanding their portfolio in the rare disease sector.
Market Segments:
- By Type: Alpha Thalassemia Silent Carrier, Alpha Thalassemia Carrier, Hemoglobin H Disease, Alpha Thalassemia Major
- By Treatment: Folic Acid Supplement, Iron ChelatorsDeferoxamine (Desferal), DeferasiroxExjade, Jadenu, Deferiprone or L1 (Ferriprox), Blood Transfusion, Stem Cell Transplant
- By End User: Hospitals, Ambulatory Surgical Centers, Others
- By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Top Companies:
- Agios Pharmaceuticals, Inc.
- Actis
- Novartis Pharmaceuticals Corporation
- Global Calcium PVT LTD
- CHIESI Farmaceutici S.p.A.
- Taro Pharmaceutical Industries Ltd.
- Amgen Inc.
- Sun Pharmaceutical Industries Ltd.
- FRESENIUS SE & Co. KGaA
- Acceleron Pharma
Customize Your Scope: https://www.datamintelligence.com/customize/alpha-thalassemia-market
Regional Growth
North America Accounted for Approximately 44.7% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment
The growing demand for alpha thalassemia treatments in healthcare is creating opportunities for manufacturers in North America to expand their operations. With a large number of producers and suppliers in the region, combined with rapid economic growth, industrial production has surged, driving the need for iron chelators in treatment.
Increased healthcare spending, rising patient adoption, technological advancements in testing and treatment, and the growth of pharmaceutical businesses across North America are all contributing to the market’s expansion.
Key Development
On March 31, 2023, Health Canada approved FERRIPROX MR, a 1000 mg extended-release deferiprone tablet, for the treatment of transfusional iron overload caused by thalassemia syndromes, sickle cell disease (SCD), or other forms of anemia, when current chelation therapy is inadequate. This approval comes from Chiesi Global Rare Diseases, a subsidiary of Chiesi Group, dedicated to providing innovative treatments and solutions for individuals affected by rare diseases.
